Neuropathix, Inc. [KLFE]

Source: 

Company Overview

We are a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our proprietary synthetic cannabinoid derivatives platform potentially useful for a broad range of inflammatory and neuropathic pain related diseases. In our eleven (11) years of operations, dating back to August 2010 under the name Kannalife Sciences, Inc. we have been principally involved in the research and development of new chemical entities (NCEs) such as KLS-13019; KLS-13022 (linoneyldihydroxybenzyl ethoxycarbonyl azetidine or LEA); its related molecules; and synthetic cannabidiol (CBD) therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with third parties who are considered leaders in active pharmaceutical (APIC) contract manufacturing, formulation; and contract bulk drug manufacturing. Most all of the operations of the Company to date at Kannalife Sciences have been in the pre-clinical stage of drug discovery. In 2019 the Company began commercialization efforts for over-the-counter cosmeceutical uses of LEA, the Companys lead compound designed to address topical skin disorders.